Korean PRRSV Vaccine Composition for Specific Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of a commercially available vaccine suitable for Korean-type Porcine Reproductive and Respiratory Syndrome Virus (PRRSV), necessitating the development of a vaccine specific to Korean variants to effectively prevent and diagnose PRRSV infections.
Innovation Solution
A novel Korean-type PRRSV strain (KCTC 12096BP) is isolated and used to create a vaccine composition, which includes the virus as an effective ingredient, along with suitable adjuvants and carriers, administered to pigs to induce immunity and prevent PRRSV, while also providing a diagnosis kit for detecting the virus.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a commercially available vaccine is used for Korean-type PRRSV, then vaccination can be performed, but the vaccine is not specific to Korean variants and may not effectively prevent infection
Solution Approach 1:
The patent applies local quality by developing a vaccine specifically tailored to the Korean-type PRRSV variant, using locally isolated virus strains (Korean-1, Korean-2, Korean-3) rather than using a universal vaccine formulation. This ensures the vaccine antigens match the specific viral characteristics of Korean pigs, improving both effectiveness and specificity simultaneously.
Solution Approach 2:
The patent utilizes parameter changes by modifying the viral strain characteristics through controlled passage numbers (3rd, 5th, 7th, 9th, 11th, 13th passages) and adjusting virus titers (10^4.0-10^6.0 TCID50/ml). These parameter adjustments optimize the vaccine's immunogenicity while maintaining safety, creating a Korean-specific vaccine formulation that differs from commercial vaccines in terms of viral origin and characteristics.
2Loss of time
If existing PRRSV vaccines are used, then vaccination can be administered, but virus shedding time is prolonged and inflammatory responses occur
Solution Approach 1:
The patent applies preliminary action by pre-passaging the virus through specific cell lines (porcine alveolar macrophages, MARC-145 cells) before vaccine formulation, performing this preparation in advance to achieve the optimal passage number (3rd-13th passage) that balances immunogenicity with reduced pathogenicity. This preliminary viral preparation reduces virus shedding time and minimizes inflammatory responses when the vaccine is administered.
Solution Approach 2:
The patent uses parameter changes by controlling the virus titer within a specific range (10^4.0-10^6.0 TCID50/ml) and adjusting the passage number to optimize the balance between immunogenicity and safety. These parameter adjustments are specifically designed to reduce virus shedding duration and minimize inflammatory responses compared to conventional vaccines.
3Reliability
If a Korean-type PRRSV vaccine is developed, then specific immunity to Korean variants is achieved, but vaccine development and validation require extensive time and resources
Solution Approach 1:
The patent applies preliminary action by pre-isolating and pre-passaging the Korean-type PRRSV strains in the laboratory before vaccine formulation. The virus has been pre-cultured in porcine alveolar macrophages and MARC-145 cells through multiple passages (3rd-13th), and the viral characteristics have been pre-characterized. This preliminary preparation significantly reduces the time required for subsequent vaccine development and validation phases.
Solution Approach 2:
The patent uses copying by creating multiple cloned virus strains (Korean-1, Korean-2, Korean-3) from the original isolated virus, each maintained through controlled passages. These cloned strains serve as standardized templates for vaccine production, allowing parallel development and validation processes that accelerate the overall timeline while ensuring consistent viral characteristics.
4Productivity
If commercial vaccines are used, then production can be maintained, but the vaccines do not reduce virus shedding time and may cause inflammatory responses
Solution Approach 1:
The patent applies parameter changes by adjusting the virus titer to a specific range (10^4.0-10^6.0 TCID50/ml) and controlling the passage number (3rd-13th passage) to optimize the balance between maintaining pig production and reducing virus shedding duration. These parameter adjustments are specifically designed to achieve faster virus clearance while maintaining adequate immunogenicity for production sustainability.
Data Source
AI summary
The present invention relates to a Korean-type porcine reproductive and respiratory syndrome virus (PRRSV) and a vaccine composition using the same, and a method for preventing porcine reproductive and respiratory syndrome. Korean-type porcine reproductive and respiratory syndrome virus with accession number KCTC 12096BP according to the present invention is Korean-type porcine reproductive and respiratory syndrome virus distinguished from European strains and North American strains, and a vaccine composition specific to Korean-type porcine reproductive and respiratory syndrome virus is produced, thereby preventing a Korean-type porcine reproductive and respiratory syndrome virus or specifically diagnosing the infection with Korean-type porcine reproductive and respiratory syndrome virus.